Market Insight: Advanced Endovascular Technologies Reshape Aortic Aneurysm Treatment

The global aortic aneurysm market is valued at USD 5.6 billion in 2026 and is projected to reach USD 17.35 billion by 2036, with a projected CAGR of 11.97% during 2027–2036. This growth reflects the increasing importance of advanced vascular interventions, improved diagnostic capabilities, and minimally invasive treatment approaches. As healthcare providers seek to manage complex aortic conditions more effectively, demand is shifting toward technologies that combine procedural precision, durable outcomes, and reduced treatment-related complications.

Endovascular aneurysm repair (EVAR) has become an important treatment approach because it can address selected aneurysms through catheter-based procedures rather than conventional open surgery. Continued development of stent grafts, expandable endoprostheses, and specialized vascular closure devices is helping physicians manage anatomically challenging cases while supporting less invasive treatment pathways. These technologies are particularly relevant for patients who may benefit from avoiding the greater surgical burden associated with open repair, although suitability depends on individual anatomy and clinical circumstances.

Recent product developments also indicate that innovation is extending beyond the primary graft itself. Bridging stents, embolic materials, and vascular closure systems are becoming important components of a broader treatment ecosystem. For manufacturers, this creates opportunities to differentiate products through deliverability, anatomical adaptability, procedural efficiency, and long-term reliability rather than relying exclusively on device availability.

The commercial implications extend to hospitals and healthcare systems. As procedural capabilities expand, providers must evaluate equipment costs, clinician training, patient selection, and follow-up requirements alongside clinical outcomes. Companies that demonstrate consistent performance in complex procedures and provide practical support for vascular teams may be better positioned to establish lasting relationships with healthcare providers.

Regional Analysis: North America Leads While Asia Pacific Gains Momentum

Regional performance in the aortic aneurysm market reflects differences in healthcare infrastructure, diagnostic access, specialist availability, and the maturity of vascular intervention services. North America accounted for 48.76% of the market in 2026, supported by established vascular care pathways, advanced diagnostic imaging, strong hospital infrastructure, and comparatively high adoption of aneurysm management procedures. Asia Pacific, meanwhile, is projected to grow at an 11.76% CAGR, driven by expanding hospital capabilities, improved vascular diagnosis, and wider access to specialist care.

North America's established position provides medical device companies with an environment in which advanced technologies can be evaluated and integrated into existing clinical workflows. Experienced vascular teams, specialist hospitals, and established procedural infrastructure can support the introduction of sophisticated endovascular devices. However, competition in mature markets can be demanding, making clinical evidence, product reliability, and differentiation important factors in purchasing decisions.

Asia Pacific presents a different opportunity. The expansion of healthcare infrastructure and growing access to diagnostic services can help identify patients who previously had limited opportunities for timely evaluation and treatment. As hospitals strengthen their vascular intervention capabilities, demand may increase for endovascular grafts, delivery systems, and supporting devices suitable for local clinical requirements.

Industry Challenge: Balancing Device Innovation, Clinical Complexity, and Long-Term Durability

One of the central challenges in the aortic aneurysm market is developing devices that can accommodate complex vascular anatomies while maintaining reliable long-term performance. Aneurysms vary in location, size, shape, and proximity to important branch vessels. These differences can complicate device selection and deployment, particularly when standard endovascular solutions are unsuitable for a patient's anatomy.

Endovascular procedures have created new treatment possibilities, but their success depends on more than minimally invasive access. Stent graft positioning, anatomical compatibility, secure fixation, and the risk of complications must all be considered. Devices intended for complex repairs must offer sufficient flexibility and precision without compromising structural integrity. Long-term durability is especially important because device-related complications may require additional monitoring or reintervention.

Recent industry developments illustrate how manufacturers are addressing these challenges. Bentley's BeFlared bridging stent graft system is designed to support complex fenestrated endovascular aneurysm repair (FEVAR) and branched endovascular aneurysm repair (BEVAR) procedures. Meanwhile, Endoron Medical's catheter-based endostapling technology targets fixation challenges in endovascular abdominal aortic aneurysm repair. These approaches address different technical problems, demonstrating that the industry's innovation agenda extends beyond conventional graft design.

Manufacturers consequently face a dual challenge: demonstrating that their technologies address specific clinical needs and establishing that the benefits justify their adoption. Evidence from clinical studies and real-world use can help distinguish meaningful advances from incremental product changes.

Product and Technology Comparison: Conventional Open Repair Versus Endovascular Aneurysm Repair

Aortic aneurysm treatment involves different approaches, with open surgical repair and endovascular aneurysm repair representing two important options. Their clinical requirements, procedural characteristics, and infrastructure needs create distinct opportunities for device manufacturers and healthcare providers.

Comparison factor	Open surgical repair	Endovascular aneurysm repair (EVAR)
Treatment approach	Direct surgical access to the affected aorta	Catheter-based placement of a stent graft within the aorta
Procedural considerations	Requires major surgery and direct access to the affected vessel	Requires suitable vascular anatomy and accurate device deployment
Recovery considerations	Generally involves a greater surgical burden	May offer a less invasive treatment pathway for appropriately selected patients
Technology requirements	Surgical instruments, grafts, and operating-room capabilities	Endovascular grafts, delivery systems, imaging, and related devices
Key considerations	Operative fitness, surgical complexity, and graft durability	Anatomical suitability, device fixation, endoleak risk, and continued surveillance

The choice between these approaches depends on aneurysm characteristics, patient health, anatomy, available expertise, and clinical judgment. EVAR is not suitable for every patient, and less invasive treatment does not eliminate the need for follow-up. Device-related complications and the possibility of further intervention remain important considerations.

From a market perspective, endovascular treatment creates demand for an interconnected range of technologies. Stent grafts form the core of many procedures, while bridging stents can support complex repairs and vascular closure devices help clinicians manage access sites. Embolic technologies may also contribute to selected vascular interventions.

Innovations are increasingly focused on addressing specific limitations within this treatment pathway. Bentley's bridging stent graft development targets complex repair procedures, while Vivasuture Medical's PerQseal Elite is designed to support vascular closure through a bioresorbable, sutureless approach. Although these technologies serve different procedural purposes, both illustrate how specialized devices can contribute to the broader evolution of minimally invasive vascular care.

Geographic Opportunity: Four Markets to Watch in Aortic Aneurysm Care

Geographic opportunities in the aortic aneurysm market depend on the maturity of vascular services, access to advanced imaging, availability of specialist clinicians, and the ability of healthcare systems to adopt sophisticated interventions. While North America currently holds a leading market position and Asia Pacific is a high-growth region, individual countries offer different strategic advantages.

United States: An established market for advanced vascular technologies

The United States is an important strategic market because its advanced hospital infrastructure and established vascular care pathways support the use of sophisticated diagnostic and treatment technologies. Demand for devices that address complex anatomy, improve deployment precision, and support procedural efficiency creates opportunities for manufacturers with differentiated clinical offerings.

Companies entering this market must also navigate demanding regulatory requirements, reimbursement considerations, and hospital purchasing processes. Clinical evidence and physician familiarity can be particularly important when introducing technologies that change established treatment practices. Building relationships with specialist centers and demonstrating practical advantages in complex procedures may therefore be central to commercial success.

China: Expanding opportunities through healthcare development

China represents a strategically relevant market within Asia Pacific as healthcare infrastructure and access to diagnostic services continue to develop. Greater diagnostic access can support earlier identification of vascular conditions, while improvements in hospital capabilities may expand the availability of advanced interventions.

However, commercial opportunities depend on local regulatory approvals, procurement requirements, pricing pressures, and access to specialist expertise. Manufacturers may need to adapt distribution strategies and provide clinical training to support adoption. Understanding local healthcare purchasing structures is as important as offering technically advanced devices.

India: Potential for broader access to vascular diagnosis and treatment

India offers opportunities associated with the development of specialist healthcare services and the expansion of advanced treatment capabilities beyond major metropolitan centers. As hospitals strengthen diagnostic and interventional infrastructure, demand may emerge for devices that balance performance with affordability and practical usability.

A key consideration is that access to complex vascular procedures can differ considerably between healthcare facilities. Companies seeking to expand in India may benefit from partnerships with established hospital networks, clinician education, and distribution models suited to varied institutional resources. Affordability and service support will remain important alongside device innovation.

Japan: A strategic market for specialized vascular solutions

Japan is relevant for manufacturers seeking to serve a technologically advanced healthcare environment with established clinical capabilities. Specialized endovascular devices may offer opportunities where clinicians require precise deployment and solutions suited to challenging vascular anatomies.

Competitive Landscape: Device Innovation Moves Beyond Conventional Stent Grafts

Competition in the aortic aneurysm market increasingly reflects specialization across the treatment pathway. Established medical device companies, emerging technology developers, and manufacturers of complementary vascular products are pursuing different ways to address clinical challenges. Recent developments suggest that competitive differentiation depends not only on core graft technology but also on fixation, vascular closure, embolization, and the management of complex anatomy.

Several developments illustrate these strategic priorities:

- Nectero and Boston Scientific: In April 2026, Nectero, supported by Boston Scientific, reported positive mid-stage clinical results for its EAST System, which uses polymer gel therapy. The reported findings indicated slowed abdominal aortic aneurysm growth in 90% of patients over two years. The ongoing Phase II/III trial remains important for evaluating the therapy's potential role in disease management. If further evidence supports its effectiveness and safety, this approach could broaden the range of technologies considered in aneurysm care beyond conventional mechanical repair.

- W. L. Gore & Associates: In July 2025, the company secured CE Mark approval for its lower-profile GORE VIABAHN VBX Balloon Expandable Endoprosthesis. Its compatibility with smaller sheaths supports its potential use in complex FEVAR and BEVAR procedures. The development highlights the importance of delivery-profile improvements and procedural flexibility in treating challenging vascular anatomies.

- Vivasuture Medical: In June 2025, the company received approval for PerQseal Elite, a bioresorbable, sutureless vascular closure device. The technology targets large-bore vascular access closure, an important consideration in endovascular interventions. Its development illustrates how improvements in supporting procedural technologies can contribute to the overall treatment experience.

- Bentley: In November 2024, Bentley announced the first-in-human implantation of its BeFlared bridging stent graft system. Designed for complex endovascular repairs, the device addresses the technical demands of bridging stents and anatomical precision. The milestone underscores the industry's focus on specialized components for complex aortic procedures.

- Endoron Medical: In July 2024, Endoron secured Series A funding from Sofinnova Partners to advance its Aortoseal catheter-based endostapling system. The investment supports further clinical validation and development of a technology designed to improve fixation in endovascular abdominal aortic aneurysm repair. It also demonstrates the role of specialist investment in advancing early-stage vascular technologies.

- Terumo Aortic: In July 2024, the company completed its first commercial implantation of the Fenestrated TREO device in Asia. The development reflects efforts to expand access to advanced endovascular aneurysm repair solutions in regional markets.

- Shape Memory Medical: In March 2024, the company closed a Series C financing round of USD 38 million to support the expansion of its shape-memory polymer-based embolic technology. The investment highlights continuing interest in materials science and specialized embolization solutions for vascular conditions.

Recent Industry News: Key Aortic Aneurysm Developments from March 2024 to April 2026

Recent developments across the aortic aneurysm industry demonstrate how clinical research, regulatory milestones, commercial launches, and investment are shaping the direction of vascular care. Rather than concentrating exclusively on conventional grafts, companies are addressing disease progression, complex anatomical repair, vascular access management, and embolization.

April 2026 — Nectero reports positive mid-stage clinical results

Nectero, supported by Boston Scientific, reported results from its EAST System, with slowed abdominal aortic aneurysm growth observed in 90% of patients over two years. The ongoing Phase II/III trial represents an important step in evaluating the therapy. The development is noteworthy because it explores an approach focused on disease progression rather than relying exclusively on mechanical aneurysm repair. Further clinical validation will be necessary to establish its potential clinical role.

June 2025 — Vivasuture Medical advances vascular closure technology

Vivasuture Medical received approval for PerQseal Elite, a bioresorbable, sutureless vascular closure device designed for large-bore access sites. The development addresses a supporting but clinically significant aspect of endovascular procedures. Technologies that simplify vascular closure may help improve workflow, although their practical value depends on clinical performance and suitability for individual patients.

November 2024 — Bentley announces a first-in-human implantation

Bentley announced the first-in-human implantation of its BeFlared bridging stent graft system. The milestone marks progress in developing specialized components for complex endovascular aneurysm repair. It also reflects the growing importance of devices designed to accommodate demanding anatomical configurations rather than relying solely on standard graft solutions.

July 2024 — Endoron Medical secures Series A funding

Endoron Medical secured USD 10 million in Series A funding from Sofinnova Partners to accelerate clinical validation and development of its Aortoseal catheter-based endostapling system. The investment demonstrates continued financial interest in technologies that address fixation and durability challenges in endovascular repair.

July 2024 — Terumo Aortic completes its first commercial implantation in Asia

Terumo Aortic completed the first commercial implantation of its Fenestrated TREO device in Asia. The development represents a regional commercialization milestone and illustrates how manufacturers are extending access to specialized aneurysm repair technologies beyond established markets.

March 2024 — Shape Memory Medical closes a Series C financing round

Shape Memory Medical closed a USD 38 million Series C financing round to expand its shape-memory polymer-based embolic technology. The financing highlights investor interest in specialized materials and embolic solutions that may serve complex vascular treatment needs.

Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/aortic-aneurysm-market-14491

About

Fundamental Business Insights:

Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.

Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email:  sales@fundamentalbusinessinsights.com

Read This Report in Regional Languages - 

https://www.fundamentalbusinessinsights.com/ko/industry-report/aortic-aneurysm-market-14491

https://www.fundamentalbusinessinsights.com/ja/industry-report/aortic-aneurysm-market-14491

https://www.fundamentalbusinessinsights.com/de/industry-report/aortic-aneurysm-market-14491

https://www.fundamentalbusinessinsights.com/it/industry-report/aortic-aneurysm-market-14491

https://www.fundamentalbusinessinsights.com/es/industry-report/aortic-aneurysm-market-14491

https://www.fundamentalbusinessinsights.com/fr/industry-report/aortic-aneurysm-market-14491